For the first quarter (end-December 31), BD is projecting sales of $5.3 billion, up 25.6% compared to the same period of fiscal 2020, and up 24.2% after currency adjustments. The company said it saw sales of $865 million from COVID-19 testing sales, of which $685 million consisted of sales of its BD Veritor product.
In the company's BD Medical segment, first-quarter revenues are expected to hit $2.3 billion, an increase of 7% after currency adjustments, while in its BD Life Sciences segment, the firm expects sales of $2.0 billion, a 74.2% increase after currency adjustments. This segment includes the company's COVID-19 testing business.
Copyright © 2021 LabPulse.com